Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Swiss Federal Institute of Technology Lausanne (Epfl)
Headquarters: Lausanne, Switzerland
Website: http://www.epfl.ch
Year Founded: 1853
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 3, 2024
Discovery & Translation
Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight
BioCentury’s roundup of translational innovations
BioCentury | Jun 29, 2024
Discovery & Translation
Science Spotlight: Microglial transplantation for ALSP, AlaMab’s osteosarcoma mAb and more
BioCentury’s roundup of translational innovations
BioCentury | Mar 28, 2024
Emerging Company Profile
Vandria: renewing mitochondria to treat CNS, muscle and other diseases
Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the clinic for mild cognitive impairment
BioCentury | Jan 12, 2024
Discovery & Translation
Neutrophil reprogramming in tumors; plus Red Queen, Orbis platforms and more
BioCentury’s roundup of translational innovations
BioCentury | May 26, 2023
Discovery & Translation
Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID vaccine and more
BioCentury’s roundup of translational news
BioCentury | Mar 16, 2023
Data Byte
Translational spotlight on variant-proofing tech for COVID and beyond
Host targets and antiviral strategies with efficacy across multiple viruses in BioCentury’s Distillery
BioCentury | Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Nov 30, 2022
Discovery & Translation
Acuitas’ pan-influenza mRNA vaccine; plus Opna links FMR1 to cancer and more
BioCentury’s roundup of translational news
BioCentury | Nov 2, 2022
Finance
Nov. 1 Quick Takes: Clinical-stage OrsoBio debuts with in-licensed metabolic pipeline
Plus: Nuvalent raises $230M and updates from NIAID, Immunochina, CorreGene
Items per page:
1 - 10 of 38